Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study

Paul M McKeigue 1 - 6 + 6, David A McAllister 2 - 6 + 6, Chris Robertson 3 - 6 + 6, Sharon Hutchinson  $\begin{array}{cc}4&6\end{array}$ , Stuart McGurnaghan  $\begin{array}{cc}5\end{array}$ , Diane Stockton  $\begin{array}{cc}6\end{array}$ , Helen M Colhoun  $\begin{array}{cc}5\end{array}$ for the PHS COVID-19 Epidemiology and Research Cell<sup>6</sup>

1 Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland.

**2** Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ.

3 Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ.

4 School of Health and Life Sciences, Glasgow Caledonian University. SH - Professor of Epidemiology and Population Health

5 Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XUC, Scotland.

6 Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE

\* Corresponding author: paul.mckeigue@ed.ac.uk

## Abstract

1

21

Objectives - To determine whether COVID-19 efficacy varies with clinical risk category 2 and to investigate risk factors for severe COVID-19 in those who have received two doses of 3 vaccine. 4 **Design** - Matched case-control study (REACT-SCOT). 5 Setting - Population of Scotland from 1 December 2020 to 8 September 2021. 6 Main outcome measure - Severe COVID-19, defined as cases with entry to critical 7 care or fatal outcome. 8 **Results** - Efficacy against severe COVID-19 of two doses of vaccine was 94% (95) 9 percent CI 93% to 96%) in those without designated risk conditions, 89% (95 percent CI 10 86% to 91%) in those with moderate risk conditions, but only 73% (95 percent CI 64% to 11 79%) in those designated as clinically extremely vulnerable (CEV) and eligible for shielding. 12 Of the 641 cases of severe COVID-19 in double-vaccinated individuals, 47% had 13 moderate risk conditions and 38% were CEV. In the double-vaccinated CEV group, the rate 14 ratio for severe disease (with no risk condition as reference category) was highest in solid 15 organ transplants at 101 (95% CI 47 to 214) but even in this subgroup the absolute risk of 16 severe COVID-19 was low (35 cases in 23678 person-months of follow-up). 17 Conclusions - Two doses of vaccine protect against severe COVID-19 in CEV 18 individuals but the residual risk in double-vaccinated individuals remains far higher in those 19 who are CEV than in those who are not. These results lay a basis for determining eligibility 20 for additional measures including passive immunization to protect those at highest risk.

## Introduction

22

36

37

38

51

The REACT-SCOT matched case-control study was established by Public Health Scotland 23 at the beginning of the epidemic to investigate risk factors for severe COVID-19 [1]. Using 24 this framework, we have reported on the relation of severe COVID-19 to risk conditions 25 including those designated as clinically extremely vulnerable (CEV) and therefore eligible 26 for the shielding programme in Scotland [1–3]. We have previously reported a comparison of 27 the efficacy of vaccination against severe COVID-19 between CEV people and those with 28 moderate risk conditions or no risk conditions, based on data up to 16 March 2021 [4]. At 29 this time few individuals had received a second dose of vaccine, but since then most CEV 30 individuals have received two doses. This report updates and extends the earlier analyses, 31 with the following objectives: 32

- 1. To determine whether vaccine efficacy varies with risk category and CEV status now 33 that more data, including exposure to two doses of vaccine, are available and now that 34 the Delta variant is the dominant variant in Scotland. 35
- 2. To investigate risk factors for severe or hospitalised COVID-19 in those who have received two doses of vaccine.

## Methods

We used the REACT-SCOT study to take advantage of data linkages already established. 39 The design has been described in detail previously [1]. In brief, for every incident case of 40 COVID-19 in the population ten controls matched for one-year age, sex and primary care 41 practice and alive on the day of presentation of the case that they were matched to were 42 selected using the Community Health Index database. COVID-19 cases are those with a 43 positive nucleic acid test, or a hospital admission or death with COVID-19 ICD-10 codes. 44 The REACT-SCOT case-control dataset is refreshed regularly and is linked to the 45 vaccination database and to the regularly updated dataset of all individuals deemed eligible 46 for the shielding programme. Though the data extract included cases presenting up to 22 47 September 2021, the analyses reported here are restricted to cases and controls presenting 48 from 1 December 2020 to 8 September 2021, ensuring follow-up for at least 14 days after 49 presentation date to allow cases to be classified as severe or hospitalised. 50

## Classification of risk categories

As previously [1], to minimise ascertainment bias we pre-specified the primary outcome 52 measure as severe COVID-19, defined as diagnosed cases with entry to critical care within 53 28 days of presentation or fatal outcome (any death within 28 days of a positive test or any 54 death for which COVID-19 was coded as underlying cause). Cases and controls were 55 classified into three broad risk categories: no risk condition; at least one of the moderate 56 risk conditions designated by public health agencies [1]; or CEV (eligible for shielding) [3]. 57 For further analyses, the CEV category was subdivided as described previously into six 58 categories: solid organ transplant, specific cancers, severe respiratory conditions, other rare 59 conditions, on immunosuppressants, and additional conditions [3]. This corresponds to the 60 list used by Public Health Scotland [5], after combining the small numbers in the group 61

"pregnant with heart disease with the "other conditions" category. For additional analyses 62 the category "specific cancers" was split to allocate cancers of blood-forming organs 63 (ICD-10 codes C81-C88, C90-C96) to a separate category. 64

#### Statistical analysis

The matched design controls for age, sex, general practice and calendar time to single day. 66 Covariates included in the models were those that have been previously identified as strong 67 predictors of severe disease in this population: care home residence, number of adults in 68 household, number of non-cardiovascular drug classes dispensed and recent hospital stay 69 [1–3]. For care home residents the number of of adults in the household was coded as 1 to 70 ensure that these two variables are not confounded. The number of non-cardiovascular drug 71 classes was calculated as the number of distinct BNF subparagraph codes for which a 72 prescription was dispensed between 15 and 255 days before presentation date. The number 73 of hospital diagnoses was calculated as the number of distinct ICD-10 chapters represented 74 at least once in hospital discharge records between 25 days and 5 years before presentation 75 date. Recent hospital stay was defined as any in-patient stay from 5 to 14 days before 76 presentation date. 77

Vaccination status was coded as the number of doses administered at least 14 days 78 before presentation date. Vaccine doses administered less than 14 days before presentation 79 date were ignored. The effect of vaccination in each of the clinical vulnerability categories 80 was estimated in a conditional logistic regression model specifying effects  $\beta_{R2}, \ldots, \beta_{RJ}$  for 81 the log rate ratio associated with risk categories 2 to J ( $\beta_{R1} = 0$  for the reference category 82 J = 1), and nested effects  $\beta_{V1}, \ldots, \beta_{VJ}$  for the log rate ratio associated with vaccination in 83 each of the J risk categories. With this incidence density sampling design, the conditional 84 odds ratio is the rate ratio. The efficacy of vaccination is 1 minus the rate ratio [6]. The 85 unconditional odds ratios calculated from frequency tables of the vaccination status of cases 86 and controls in each risk group cannot be used to estimate rate ratios [7,8]. 87

### Cohort analysis of the shielding list

The case-control study estimates only rate ratios. To investigate how the absolute rates of 89 severe disease in those listed as clinically extremely vulnerable have changed with the 90 vaccination programme rollout, we also undertook a cohort analysis of all individuals who 91 had ever been on the shielding list. A Poisson regression model was fitted to the cohort 92 formatted with one observation per 28-day person-time interval, and individuals censored at 93 first diagnosis of COVID-19. Event status was defined as severe COVID-19 presenting 94 within the person-time interval, and the covariates were sex, baseline age, and shielding 95 eligibility group. The baseline hazard rate was modelled as a natural spline function of 96 calendar time with 6 degrees of freedom. To allow comparison with how the rates of all 97 diagnosed cases varied with calendar time, a similar model was fitted with event status 98 defined as any diagnosed case. 99

## Results

### Relation of vaccine efficacy to risk conditions

As shown in Table 1 from 1 December 2020 to 8 September 2021 there were 5644 cases of severe COVID-19 in the total population of Scotland of whom 28% had no designated risk condition, 51% had a moderate risk condition and 21% were CEV. The distributions in cases and controls of other risk factors included as covariates in the models are shown for completeness. Overall 80% of severe cases arising in this period were not yet vaccinated. Table S1 shows the same tabulation with case definition broadened to include all 21671 hospitalised cases and their matched controls.

Table 2 shows rate ratios associated with 1 and 2 vaccine doses (with 0 doses as reference 109 category) in each of the three broad risk categories from the conditional logistic regression 110 model. The model included risk categories (no risk conditions as reference category), care 111 home residence, number of adults in household, number of drug classes and recent hospital 112 stay as covariates. The rate ratio associated with two doses of vaccine was 0.06 (95% CI)113 0.04 to 0.07) in those without risk conditions, 0.11 (95% CI 0.09 to 0.14) in those with 114 moderate risk conditions, and 0.27 (95% CI 0.21 to 0.36) in the CEV group. On the scale of 115 efficacy, these estimates are equivalent to 94% (95 percent CI 93% to 96%) in those without 116 risk conditions, 89% (95 percent CI 86% to 91%) in those with moderate risk conditions, 117 and 73% (95 percent CI 64% to 79%) in the CEV group. Table S2 shows the same model 118 with case definition broadened to include all hospitalised cases and their matched controls: 119 the efficacy of 2 doses against hospitalisation also was lower at 68% (95 percent CI 63% to 120 71%) in the CEV than in the other two risk categories. The difference in vaccine efficacy 121 against hospitalisation between the CEV group and the other two risk categories was not 122 explained by differences in time since second dose. 123

Table 3 shows rate ratios associated with vaccination by risk group with the CEV group 124 subdivided into six categories. Rate ratios were higher (and thus efficacy was lower) in all 125 CEV subgroups than in those without risk conditions or with moderate risk conditions, but 126 the confidence intervals were too wide for comparisons of efficacy between CEV subgroups. 127 Within the "Specific cancers" group, efficacy of two doses did not differ between those with 128 blood cancers and those with other types of cancer but the confidence intervals were wide. 129 Table S3 shows rate ratios for the first and second dose with the case definition broadened 130 to include all hospitalised cases and their matched controls. In this table the highest rate 131 ratio (lowest efficacy) is in solid organ transplant recipients but again the confidence 132 intervals are too wide for comparisons of efficacy between CEV subgroups. 133

We examined whether there was any difference in efficacy by class of vaccine and 134 whether any such differences varied by risk category. Table 4 shows rate ratios associated 135 with 1 and 2 doses of each class of vaccine (with 0 doses as reference category) in each of 136 the three broad risk categories. Table S4 shows the same model with case definition 137 broadened to include all hospitalised cases and their matched controls. Although the 138 confidence intervals for the rate ratios associated with 1 or 2 doses of each vaccine product 139 in the CEV group are wide, it is clear that for both classes of vaccine product the efficacy of 140 2 doses is lower in the CEV group than in those with moderate risk conditions or no risk 141 conditions. Efficacy of two doses against severe COVID-19 in the CEV group did not differ 142 between the AstraZeneca vaccine [72% (95 percent CI 63% to 79%)] and the mRNA 143 vaccines [73% (95 percent CI 59% to 83%)] Further comparison of efficacy of the two 144

100

101

102

103

104

105

106

107

vaccine types in CEV individuals has been reported elsewhere [9].

145

146

164

177

178

#### Risk factors for severe COVID-19 in the double-vaccinated

Table 5 shows risk factors for severe COVID-19 in cases and controls who had received 2 147 doses of vaccine at least 14 days before presentation date. Table S5 shows the same analysis 148 with case definition broadened to include hospitalized cases and matched controls who had 149 received 2 doses of vaccine. Only 15% of double-vaccinated severe cases had no designated 150 risk condition: 47% had at least one moderate risk condition and 38% were CEV. Of the 151 variables that we have previously reported as risk factors for severe COVID-19 in the general 152 population, care home residence and socioeconomic deprivation were not associated with 153 severe disease in the double-vaccinated. In this group the risk factors for severe disease were 154 designated risk conditions, other indicators of co-morbidity including numbers of hospital 155 diagnoses and drug classes prescribed and transmission-related factors including number of 156 adults in household and recent hospital stay. A risk score for hospitalised or fatal COVID-19 157 in the double-vaccinated calculated from the multivariable conditional logistic regression 158 model in Table S5 was able to distinguish severe cases from noncases with a C-statistic of 159 0.79. Among the CEV groups, the highest rate ratio for severe disease was solid organ 160 transplant recipients: with no risk conditions as reference category, the unadjusted rate 161 ratio associated with receipt of a solid organ transplant among the double-vaccinated was 162 101 (95% CI 47 to 214) for severe disease and 29.9 (95% CI 21.0 to 42.7) for hospitalisation. 163

#### Shielding cohort

By the date of the latest extract of the shielding list in July 2021, 8230 (4%) of the 202510 165 individuals who had ever been on the shielding list had been diagnosed with COVID-19, 166 and 18893 (9%) had been removed from the list for other reasons. Fig 1 shows the fitted 167 incidence per month of any diagnosis and of severe cases in Poisson regression models fitted 168 to the entire cohort. The incidence of any diagnosed COVID-19 in the shielding cohort fell 169 from 1 December to a nadir in late April. Despite the incidence of any diagnosed COVID-19 170 rising steeply from 1 May onwards, the incidence of severe COVID-19 rose only slightly. 171

Table S6 shows the incidence of severe COVID-19 in double-vaccinated CEV individuals, 172 by subgroup. In the highest risk group – solid organ transplant recipients – the incidence 173 was 1.5 per 1000 per month (35 cases in 23678 person-months of follow-up). Of the 35 174 severe cases among double-vaccinated solid organ transplants, only one had received a 175 transplant less than one year before presentation date. 176

## Discussion

## Statement of principal findings

1. Although the efficacy of two doses of vaccine against severe COVID-19 in those 179 without risk conditions remains around 90%, it is now clear that efficacy in clinically 180 extremely vulnerable individuals is somewhat lower at 73%. On the scale of absolute 181 risk reduction, a reduction by three-quarters of fivefold elevated risk in unvaccinated 182 CEV individuals is of course greater than a reduction of baseline risk by nine-tenths. 183

- 2. Among double-vaccinated individuals, those who have designated risk conditions or are CEV account for 85% of severe cases and 75% of hospitalised cases.
- In comparison with double-vaccinated individuals of the same age and sex without risk conditions, double-vaccinated CEV individuals remain at relatively high risk of severe list COVID-19. For double-vaccinated solid organ transplant recipients the rate of severe list disease is 100-fold higher, though the absolute risk is about 1 in 1000 per month.

### Strengths and limitations

190

Strengths of this study are the elimination of calendar time effects by the matched 191 case-control design, the comprehensive linkage to e-health records and the focus on severe 192 cases as main outcome measure. Hospitalised cases may include some test-positive 193 individuals whose admission or continued stay in hospital was for another underlying 194 diagnosis: this in turn may lead to underestimation of vaccine efficacy against COVID-19, 195 especially in risk groups with comorbidities. Such misclassification is less likely to occur 196 with the narrow definition of severe COVID-19 used in the REACT-SCOT study. 197

### Relation to other studies

Two studies in England have examined vaccine efficacy in the CEV. One estimated that 204 efficacy of the Pfizer vaccine against hospitalisation waned more rapidly in the CEV than in 205 those who were not CEV [10]. The other study estimated efficacy of two doses of any 206 vaccine against symptomatic COVID-19 as 87% (based on combining the age-stratified 207 estimates) in those who had been advised to shield [11]. However without regular scheduled 208 testing, estimation of vaccine efficacy against infection (rather than hospitalisation) is 209 subject to ascertainment bias, and this problem is not entirely overcome by restricting to 210 symptomatic cases or by test-negative case-control designs. 211

## Policy implications.

Our results show that the risk of severe COVID-19 after two doses of vaccine is highest in 213 solid organ transplant recipients, and that this elevated risk is not restricted to the first six 214 months after transplant as the UK Joint Committee on Vaccination and Immunisation 215 apparently assumed in its original recommendation that "a third primary dose be offered to 216 individuals aged 12 years and over with severe immunosuppression" [12]. Subsequent 217 recommendations have broadened the criteria for third primary doses and booster doses. 218 For solid organ transplant recipients, passive immunization therapies may be an option now 219 that they have been licensed in the UK for prevention in "those who have a medical 220 condition making them unlikely to respond to or be protected by vaccination" [13]. 221

203

#### **Declarations** 222 **Public and Patient Involvement statement:** 223 This study was conducted under approvals from the Public Benefit and Privacy Panel for 224 Health and Social Care which includes public and patient representatives. 225 Ethics approval 226 This study was performed within Public Health Scotland as part of its statutory duty to 227 monitor and investigate public health problems. Under the UK Policy Framework for 228 Health and Social Care Research set out by the NHS Health Research Authority, this does 229 not fall within the definition of research and ethical review was therefore not required. 230 Individual consent is not required for Public Health Scotland staff to process personal data 231 to perform specific tasks in the public interest that fall within its statutory role. The 232 statutory basis for this is set out in Public Health Scotland's privacy notice. 233 **Transparency** declaration 234 PM as the manuscript's guarantor affirms: that the manuscript is an honest, accurate, and 235 transparent account of the study being reported; that no important aspects of the study 236 have been omitted; and that any discrepancies from the study as originally planned and 237 registered have been explained. This manuscript has been generated directly from the 238 source data by a reproducible research pipeline. 239 Funding 240 No specific funding was received for this study. 241 Data Availability 242 The component datasets used here are available via the Public Benefits and Privacy Panel 243 for Health and Social Care at https://www.informationgovernance.scot.nhs.uk/pbpphsc/ for 244 researchers who meet the criteria for access to confidential data. All source code used for 245 derivation of variables, statistical analysis and generation of this manuscript is available on 246 https://github.com/pmckeigue/covid-scotland public. 247 **Competing interest** 248 All authors have completed and submitted the ICMJE Form for Disclosure of Potential 249 Conflicts of Interest.

### Acknowledgements

We thank Jen Bishop, Ciara Gribben, Bob Taylor and David Caldwell for undertaking the 252 linkage analysis within Public Health Scotland, 253

250

# References

1. McKeigue PM, Weir A, Bishop J, McGurnaghan SJ, Kennedy S, McAllister D, et al.	255
Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for	256
COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLOS	257
Medicine. 2020;17: e1003374. doi:10.1371/journal.pmed.1003374	258
2. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al.	259
Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: The	260
REACT-SCOT case-control study. BMC medicine. 2021;19: 51.	261
doi:10.1186/s12916-021-01907-8	262
3. McKeigue PM, McAllister DA, Caldwell D, Gribben C, Bishop J, McGurnaghan S, et	263
al. Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. BMC medicine.	264
2021;19: 149. doi:10.1186/s12916-021-02021-5	265
4. McKeigue PM, McAllister DA, Bishop J, Hutchinson S, Robertson C, Lone N, et al.	266 267
Efficacy of COVID-19 vaccination in individuals designated as clinically extremely	268
vulnerable in Scotland. F1000Research. 2021;10: 663. doi:10.12688/f1000research.53812.1	269
5. Health Protection Scotland. Search criteria for highest risk patients for shielding.	270
https://hpspubsrepo.blob.core.windows.net/hps-website/nss/3008/documents/1_covid-19-	271
search-criteria-highest-risk-patients.pdf: Public Health Scotland; 2020	272
May.	273
6. Rodrigues LC, Smith PG. Use of the case-control approach in vaccine evaluation:	274
Efficacy and adverse effects. Epidemiologic Reviews. 1999;21: 56–72.	275
doi:10.1093/oxfordjournals.epirev.a017988	276
7. Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple	277
relative risk functions in matched case-control studies. American Journal of Epidemiology.	278
<ul><li>1978;108: 299–307. doi:10.1093/oxfordjournals.aje.a112623</li><li>8. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control</li></ul>	279
studies. American Journal of Epidemiology. 1982;116: 547–553.	280
doi:10.1093/oxfordjournals.aje.a113439	281 282
9. McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun	283
HM, et al. Efficacy of vaccination against severe COVID-19 in relation to Delta variant and	284
time since second dose: The REACT-SCOT case-control study. Cold Spring Harbor	285
Laboratory Press; 2021. p. 2021.09.12.21263448. doi:10.1101/2021.09.12.21263448	286
10. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine	287
effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild	288
and severe COVID-19 in the UK. Public Health England; 2021 Sep.	289
doi:10.1101/2021.09.15.21263583	290
11. Whitaker HJ, Tsang RS, Byford R, Andrews NJ, Sherlock J, Pillai S, et al.	291
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune	292
response among individuals in clinical risk groups.	293
https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+pa-	294
per.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f;	295
<ul><li>2021.</li><li>12. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination</li></ul>	296
and Immunisation (JCVI) advice on third primary dose vaccination.	297
and immunisation (50 vi) advice on unite primary dose vaccination.	298

https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-	299
people-who-are-immunos uppressed-jcvi-advice/joint-committee-on-vaccination-and-induced and the second se	300
immunisation-jcvi-advice-on-third-primary-dose-vaccination: Joint Committee on	301
Vaccination and Immunisation; 2021 Sep.	302
13. Medicines & Healthcare products Regulatory Agency. Summary of Product	303
Characteristics for Ronapreve. GOV.UK.	304
https://www.gov.uk/government/publications/regulatory-approval-of-ronapreve/summary-	305
of-product-characteristics-for-ronapreve;	306
2021.	307






Fig 1. Fitted values for monthly incidence of any case and severe case in the shielding cohort, based on Poisson regression with spline terms for calendar time

	Controls $(50086)$	Cases $(5644)$
Care home	2471 (5%)	951 (17%)
SIMD quintile (integer)	3 (1  to  4)	2 (1  to  3)
Number of adults in	2 (1  to  2)	2 (1  to  2)
household		
Number of drug classes	4 (1  to  8)	8 (4  to  12)
Recent hospital stay	1062~(2%)	1479~(26%)
Risk group		
No risk condition	28661 (57%)	1576~(28%)
Moderate risk condition	17603(35%)	2891(51%)
Solid organ transplant	54 (0%)	70(1%)
Specific cancers	522 (1%)	160(3%)
Severe respiratory	1821 (4%)	504 (9%)
Rare diseases	179~(0%)	56~(1%)
On immunosuppressants	388~(1%)	104~(2%)
Additional conditions	858~(2%)	283~(5%)
Vaccination status		
Not vaccinated	36874~(74%)	4494 (80%)
1 dose mRNA vaccine	2277(5%)	247(4%)
1 dose AZ vaccine	2693(5%)	260(5%)
2 doses mRNA vaccine	2630(5%)	142 (3%)
2 doses AZ vaccine	5595 (11%)	499 (9%)

Table 1. Numbers of cases of severe COVID-19 and matched controls, by risk group and vaccine product

Presentation dates from 1 December 2020 to 8 September 2021.

Median and interquartile range given for numeric variables

Severe COVID-19 defined as entry to critical care or death

within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

Table 2. Rate ratios for severe COVID-19 within risk groups associated with vaccine dose: unvaccinated as reference category

	1 dose vaco	cine	2 doses	2 doses vaccine		
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value		
No risk condition	$0.30 \ (0.24, \ 0.38)$	$5 \times 10^{-26}$	0.06 (0.04, 0.07)	$2 \times 10^{-102}$		
Moderate risk condition	$0.42 \ (0.35, \ 0.50)$	$8 \times 10^{-20}$	$0.11 \ (0.09, \ 0.14)$	$1 \times 10^{-82}$		
Eligible for shielding	$0.53 \ (0.39, \ 0.72)$	$7  imes 10^{-5}$	$0.27 \ (0.21, \ 0.36)$	$1 \times 10^{-22}$		

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is doses administered at least 14 days fbefore presentation date

Table 3.	Rate ratios	for severe	COVID-19	associated	with	vaccine	$\operatorname{dose}$	within	clinically	
extremely	v vulnerable	subgroups	/2, 1							

	1 dose vacc	ine	2 doses vaccine		
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value	
Solid organ transplant	0.93 (0.22, 3.85)	0.9	0.60(0.24, 1.51)	0.3	
Specific cancers	$0.51 \ (0.22, \ 1.17)$	0.1	0.34 (0.20, 0.59)	$1 \times 10^{-4}$	
Severe respiratory	0.65(0.42, 1.01)	0.06	0.18(0.13, 0.26)	$9 \times 10^{-21}$	
Rare diseases	0.81 (0.26, 2.57)	0.7	0.10(0.03, 0.28)	$2 \times 10^{-5}$	
On	0.47(0.20, 1.12)	0.09	0.53 (0.29, 0.97)	0.04	
immunosuppressants					
Additional conditions	$0.24 \ (0.12, \ 0.49)$	$9  imes 10^{-5}$	$0.24 \ (0.15, \ 0.39)$	$2 \times 10^{-9}$	

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is number of doses administered at least 14 days before presentation date

#### Table 4. Rate ratios for severe COVID-19 within risk groups: vaccine dose and product encoded as categoric variable with unvaccinated as reference category

	1 dose vaccine		2 doses vaccine	
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition: mRNA vaccine	0.25(0.18, 0.34)	$7 \times 10^{-18}$	$0.04 \ (0.03, \ 0.06)$	$9 \times 10^{-46}$
No risk condition: AZ vaccine	0.35(0.26, 0.47)	$3 \times 10^{-12}$	0.07 (0.05, 0.09)	$7 \times 10^{-73}$
Moderate risk condition: mRNA vaccine	0.52(0.42, 0.65)	$2 \times 10^{-8}$	0.07 (0.05, 0.09)	$7 \times 10^{-55}$
Moderate risk condition: AZ vaccine	0.30(0.23, 0.40)	$9 \times 10^{-17}$	0.13 (0.10, 0.17)	$2 \times 10^{-60}$
Eligible for shielding: mRNA vaccine	0.48(0.28, 0.82)	0.007	$0.27 \ (0.17, \ 0.41)$	$3  imes 10^{-9}$
Eligible for shielding: AZ vaccine	$0.52 \ (0.36, \ 0.75)$	$5  imes 10^{-4}$	0.28 (0.21, 0.37)	$3  imes 10^{-19}$

Presentation dates from 1 December 2020 to 8 September 2021.

Adjusted for care home residence, number of adults in household, number of drug classes dispensed, recent hospital stay and risk category. Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

Table 5. Risk factors for severe COVID-19 in those who had received 2 doses of vaccine at least 14 days before

			Univaria	ite	Multivari	able
	$\begin{array}{c} \text{Controls} \\ (8225) \end{array}$	Cases $(641)$	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	207 (3%)	57 (9%)	3.11(2.14, 4.52)	$2 \times 10^{-9}$	1.70(1.10, 2.63)	0.02
SIMD quintile (integer)	3 (1  to  4)	2 (1  to  4)	0.79(0.74, 0.85)	$4 \times 10^{-10}$	0.92(0.84, 1.00)	0.06
Number of adults in household	2 (1  to  2)	2 (1  to  2)	$0.95 \ (0.88, \ 1.03)$	0.3	$1.01 \ (0.92, \ 1.10)$	0.9
Number of hospital diagnoses	0 (0 to 3)	5 (1 to 8)	$1.28 \ (1.25, \ 1.31)$	$8\times 10^{-75}$	1.06 (1.02, 1.09)	0.001
Number of non-cardiovascular drug classes	2 (1  to  5)	7 (4 to 10)	$1.27 \ (1.24, \ 1.30)$	$7 \times 10^{-92}$	1.13 (1.10, 1.17)	$6 \times 10^{-18}$
Recent hospital stay	151~(2%)	90 (14%)	7.5 (5.5, 10.2)	$1\times 10^{-36}$	3.83 (2.68, 5.47)	$2\times 10^{-13}$
Risk group						
No risk condition	4940 (60%)	95 (15%)				
Moderate risk condition	2673 (32%)	303 (47%)	5.4 (4.2, 7.0)	$1 \times 10^{-37}$	2.93 (2.20, 3.89)	$1 \times 10^{-13}$
Solid organ	15 (0%)	35 (5%)	101 (47, 214)	$7  imes 10^{-33}$	31.4(13.8,71.2)	$2 \times 10^{-16}$
transplant	· · ·	× /				
Specific cancers	77 (1%)	36~(6%)	26.0(15.8, 43.0)	$3 \times 10^{-37}$	12.7 (7.3, 22.0)	$2 \times 10^{-19}$
Severe respiratory	289(4%)	82 (13%)	$13.2 \ (9.3, 18.7)$	$2 \times 10^{-47}$	4.75 (3.17, 7.11)	$4 \times 10^{-14}$
Rare diseases	32 (0%)	6 (1%)	8.2(3.2, 21.1)	$1 \times 10^{-5}$	3.24(1.21, 8.66)	0.02
On	61 (1%)	31 (5%)	26.2(15.1, 45.3)	$2 \times 10^{-31}$	13.3(7.3, 24.3)	$3  imes 10^{-17}$
immunosuppressants						
Additional conditions	138~(2%)	53~(8%)	$15.5\ (10.2,\ 23.6)$	$6\times 10^{-38}$	$6.3\ (3.9,\ 10.0)$	$3\times 10^{-14}$

Severe COVID-19 is defined by entry to critical care or fatal outcome

Percentages are column percentages for each variable Rate ratios are from conditional logistic regression models matched for age, sex and general practice

Univariate rate ratios are for models with a single covariate

Multivariable rate ratios are for a model including all covariates shown in the table

## Supplementary Material

	Controls $(202071)$	Cases $(21671)$
Care home	5790~(3%)	2053~(9%)
SIMD quintile (integer)	3 (1  to  4)	2 (1  to  3)
Number of adults in	2 (1  to  2)	2 (1  to  2)
nousehold		
Number of drug classes	3 (0  to  6)	6 (2  to  10)
Recent hospital stay	3304~(2%)	5333~(25%)
Risk group		
No risk condition	133911~(66%)	8802 (41%)
Moderate risk condition	55806~(28%)	9214~(43%)
Solid organ transplant	255~(0%)	192 (1%)
Specific cancers	1600~(1%)	506~(2%)
Severe respiratory	5630~(3%)	1538~(7%)
Rare diseases	575~(0%)	157~(1%)
On immunosuppressants	1462~(1%)	330~(2%)
Additional conditions	2832~(1%)	932~(4%)
Vaccination status		
Not vaccinated	128417~(64%)	$15369\ (71\%)$
1 dose mRNA vaccine	11812 (6%)	788 (4%)
1 dose AZ vaccine	$12562\ (6\%)$	1440 (7%)
2 doses mRNA vaccine	16983 (8%)	774 (4%)
2 doses AZ vaccine	$32213\ (16\%)$	3294~(15%)

**Table S1.** Numbers of cases of hospitalized or fatal COVID-19 and matched controls, by risk group and vaccine product

Presentation dates from 1 December 2020 to 8 September 2021.

Median and interquartile range given for numeric variables Controls matched for age, sex, and primary care practice on

date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

Table S2.	Rate ratios for hopitalised or fatal COVID-19 within risk groups associated w	$\operatorname{with}$
vaccine dos	e: unvaccinated as reference category	

	1 dose vao	cine		2 doses vaccine	
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value	
No risk condition Moderate risk condition	$\begin{array}{c} 0.36 \ (0.33, \ 0.39) \\ 0.41 \ (0.37, \ 0.45) \end{array}$	$2 \times 10^{-118}$ $2 \times 10^{-70}$	$\begin{array}{c} 0.14 \ (0.12, \ 0.15) \\ 0.17 \ (0.15, \ 0.18) \end{array}$	$2 \times 10^{-408}$ $10 \times 10^{-304}$	
Eligible for shielding	$0.41 (0.57, 0.45) \\ 0.58 (0.50, 0.69)$	$\frac{2 \times 10}{5 \times 10^{-11}}$	$\begin{array}{c} 0.17 \ (0.13, \ 0.13) \\ 0.32 \ (0.29, \ 0.37) \end{array}$	$10 \times 10^{-75}$ 1 × 10 <sup>-75</sup>	

Presentation dates from 1 December 2020 to 8 September 2021.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is doses administered at least 14 days fbefore presentation date

Table S3.	Rate ratios for	hospitalised or fatal	COVID-19 a	associated with	vaccine dose
within clini	ically extremely	vulnerable subgroups	, with unva	ccinated as refe	erence category

	1 dose vaccine		2 doses vaccine		
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value	
Solid organ transplant	0.70(0.33, 1.46)	0.3	$0.60 \ (0.38, \ 0.95)$	0.03	
Specific cancers	0.88(0.59, 1.32)	0.5	0.31 (0.23, 0.41)	$2 \times 10^{-16}$	
Severe respiratory	0.55(0.43, 0.70)	$9 \times 10^{-7}$	0.28(0.24, 0.33)	$3 \times 10^{-50}$	
Rare diseases	0.48(0.25, 0.92)	0.03	0.31 (0.19, 0.50)	$1 \times 10^{-6}$	
On	0.74(0.47, 1.15)	0.2	$0.40 \ (0.29, \ 0.54)$	$2 \times 10^{-9}$	
immunosuppressants					
Additional conditions	$0.46\ (0.33,\ 0.63)$	$2  imes 10^{-6}$	$0.32 \ (0.26, \ 0.39)$	$7 \times 10^{-26}$	

Presentation dates from 1 December 2020 to 8 September 2021.

Severe COVID-19 defined as entry to critical care or death within 28 days of presentation.

Controls matched for age, sex, and primary care practice on date of presentation of case.

Adjusted for care home residence, number of adults in household, number of drug classes and recent hospital stay as covariates Rate ratios estimated in multivariable conditional logistic regression with all variables in model

Vaccination status is number of doses administered at least 14 days before presentation date

#### Table S4. Rate ratios for hospitalized or fatal COVID-19 within risk groups associated with vaccine dose by product within risk groups, with unvaccinated as reference category

	1 dose vaccine		2 doses vaccine	
Effect	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
No risk condition: mRNA vaccine	0.26 (0.23, 0.29)	$4 \times 10^{-101}$	$0.08 \ (0.07, \ 0.09)$	$4 \times 10^{-235}$
No risk condition: AZ vaccine	0.52(0.46, 0.58)	$1 \times 10^{-29}$	0.19(0.17, 0.20)	$9 \times 10^{-236}$
Moderate risk condition: mRNA vaccine	0.36(0.31, 0.41)	$3 \times 10^{-47}$	0.09(0.08, 0.11)	$5 \times 10^{-220}$
Moderate risk condition: AZ vaccine	0.48(0.42, 0.54)	$6 \times 10^{-31}$	0.22 (0.20, 0.25)	$3 \times 10^{-186}$
Eligible for shielding: mRNA vaccine	$0.41 \ (0.30, \ 0.55)$	$2  imes 10^{-9}$	$0.23 \ (0.19, \ 0.29)$	$3  imes 10^{-41}$
Eligible for shielding: AZ vaccine	$0.71 \ (0.59, \ 0.86)$	$3  imes 10^{-4}$	0.38(0.33, 0.43)	$7  imes 10^{-51}$

Presentation dates from 1 December 2020 to 8 September 2021.

Adjusted for care home residence, number of adults in household, number of drug classes dispensed, recent hospital stay and risk category. Controls matched for age, sex, and primary care practice on date of presentation of case.

Vaccination status is number of doses administered at least 14 days before presentation date

			Univariate		Multivariable	
	$\begin{array}{c} \text{Controls} \\ (8225) \end{array}$	Cases $(641)$	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	1127 (2%)	213 (5%)	1.90(1.59, 2.26)	$7  imes 10^{-13}$	$0.81 \ (0.66, \ 1.00)$	0.05
SIMD quintile (integer)	3 (1  to  4)	2 (1  to  4)	$0.81 \ (0.78, \ 0.83)$	$2 \times 10^{-49}$	$0.88 \ (0.86, \ 0.91)$	$5 \times 10^{-13}$
Number of adults in	2 (1  to  2)	2 (1  to  2)	$1.02 \ (0.99, \ 1.05)$	0.3	$1.05\ (1.02,\ 1.09)$	0.002
household						
Number of hospital diagnoses	0 (0  to  3)	4 (1  to  7)	$1.28 \ (1.27, \ 1.29)$	$2 \times 10^{-448}$	$1.09\ (1.08,\ 1.11)$	$5 \times 10^{-37}$
Number of non-cardiovascular drug	2 (1  to  5)	6 (3 to 9)	1.23 (1.21, 1.24)	$4\times 10^{-446}$	1.11 (1.10, 1.12)	$2\times 10^{-74}$
classes				205	<i>.</i> .	105
Recent hospital stay	925~(2%)	830~(20%)	$11.6\ (10.4,\ 13.1)$	$9  imes 10^{-385}$	6.6 (5.8, 7.5)	$5\times 10^{-185}$
Risk group						
No risk condition	30516 (62%)	999~(25%)				
Moderate risk	15102	1925 (47%)	3.62(3.32, 3.95)	$1 \times 10^{-184}$	1.80(1.63, 1.99)	$2 \times 10^{-30}$
condition	(31%)					
Solid organ	97(0%)	94 (2%)	29.9(21.0, 42.7)	$2 \times 10^{-78}$	$9.2 \ (6.2, \ 13.7)$	$1 \times 10^{-27}$
transplant						
Specific cancers	449 (1%)	154~(4%)	9.8 (8.0, 12.2)	$5 \times 10^{-100}$	3.86(3.04, 4.90)	$1 \times 10^{-28}$
Severe respiratory	1599~(3%)	454 (11%)	8.3(7.2, 9.5)	$3 \times 10^{-209}$	2.87(2.45, 3.37)	$1 \times 10^{-38}$
Rare diseases	162~(0%)	46 (1%)	8.2(5.7, 11.8)	$1 \times 10^{-30}$	3.46(2.33, 5.15)	$8 \times 10^{-10}$
On	461~(1%)	117 (3%)	$8.3 \ (6.6, \ 10.5)$	$1 \times 10^{-68}$	3.74(2.87, 4.86)	$9 \times 10^{-23}$
immunosuppressants						
Additional conditions	810 (2%)	279~(7%)	$10.1 \ (8.6, \ 12.0)$	$2 \times 10^{-163}$	3.67 (3.02, 4.46)	$6  imes 10^{-39}$

**Table S5.** Risk factors for hospitalised or fatal COVID-19 in those who had received 2doses of vaccine at least 14 days before

Percentages are column percentages for each variable

Rate ratios are from conditional logistic regression models matched for age, sex and general practice

Univariate rate ratios are for models with a single covariate

Multivariable rate ratios are for a model including all covariates shown in the table

**Table S6.** Incidence of severe COVID-19 in clinically extremely vulnerable individuals who had received 2 doses of vaccine at least 14 days before, by risk subgroup

Risk group	Number of severe cases	Person-months	Rate / 1000
Solid organ transplant	35	23678	1.48
Specific cancers	33	93896	0.35
Additional / rare conditions	59	210801	0.28
Severe respiratory	80	303250	0.26
On immunosuppressants	30	118649	0.25